TNF and Crohn disease: For IBD therapy, monoclonal antibodies against tumor necrosis factor such as infliximab, adalimumab, certolizumab pegol and golimumab have all been approved worldwide for the treatment of moderate-to-severe active Crohn’s disease and/or ulcerative colitis (Argollo et al., 2020).